Table II.
Kalmar (n = 5036) | Sweden total (n = 732230) | OR (95% CI) | |
Neuroleptics (N05A) | 148 (2.9%) | 3.3071 (4.5%) | 0.71 (0.60–0.84) |
Benzodiazepines (N05B) | 384 (7.6%) | 6.8644 (9.4%) | 0.90 (0.81–1.01) |
Sleeping agents (N05C) | 1032 (20.5%) | 16.7338 (22.9%) | 0.95 (0.88–1.02) |
SSRI antidepressants (N06AB) | 577 (11.5%) | 82.957 (11.3%) | 1.15 (1.05–1.26) |
Antidementia agents (N06D) | 271 (5.4%) | 20.481 (2.8%) | 2.14 (1.89–2.43) |
Drugs with anticholinergic properties | 270 (5.4%) | 42.007 (5.7%) | 1.05 (0.92–1.19) |
1The difference between Kalmar community and Sweden is expressed as an odds ratio (OR) controlled for age, gender, and number of drugs.